N-(1H-indazol-5-yl)butanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: N-(1H-indazol-5-yl)butanamide
• 化学式: C₁₁H₁₃N₃O
• mdl: MFCD08071981
• 分子量: 203.24
• InChiKey: XICIUXBJKKKUFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] HETEROCYCLIC RIP1 KINASE INHIBITORS<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE LA KINASE RIP1
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2021046447A1

  公开（公告）日：2021-03-11

  Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

  本文披露了一些激酶抑制化合物，如受体相互作用蛋白-1（RIP1）激酶抑制剂化合物，以及包含这些抑制剂化合物的药物组合物和制剂。披露的化合物、药物组合物和/或组合物可用于治疗或预防激酶相关疾病或病况，特别是RIP1相关疾病或病况。
• [EN] RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME<br/>[FR] COMPOSÉS INHIBITEURS DE RIP1 ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2021046437A1

  公开（公告）日：2021-03-11

  Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.